{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-400213","form_type":"8-K","ticker":"APVO","cik":"0001671584","company_name":"Aptevo Therapeutics Inc.","filed_at":"2026-09-24T12:10:14+00:00","discovered_at":"2026-09-24T13:00:03.502281+00:00","generated_at":"2026-09-24T13:03:47.585639+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Aptevo advances trispecific candidate APVO451; IND-enabling studies expected 1H2027","bullets":["Optimizing several trispecific candidates for reliable, scalable manufacturing, a key step toward human testing.","Lead candidate APVO451 to enter IND-enabling studies in 1H2027.","Trispecifics combine three functions: recognize cancer, activate immune cells, overcome tumor defenses.","Aptevo to present additional details at an upcoming international scientific conference."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-400213","json":"https://secwatch.observer/filing/0001193125-26-400213.json","markdown":"https://secwatch.observer/filing/0001193125-26-400213.md","text":"https://secwatch.observer/filing/0001193125-26-400213.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671584/000119312526400213/0001193125-26-400213-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671584/000119312526400213/apvo-20260924.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-24T13:03:47.585639+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}